4-((5-methyl-4-((2-oxo-2,3-dihydrobenzo[d]oxazol-5yl)amino)pyrimidin-2-yl)amino)benzonitrile

ID: ALA5194652

PubChem CID: 66659170

Max Phase: Preclinical

Molecular Formula: C19H14N6O2

Molecular Weight: 358.36

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Cc1cnc(Nc2ccc(C#N)cc2)nc1Nc1ccc2oc(=O)[nH]c2c1

Standard InChI:  InChI=1S/C19H14N6O2/c1-11-10-21-18(23-13-4-2-12(9-20)3-5-13)25-17(11)22-14-6-7-16-15(8-14)24-19(26)27-16/h2-8,10H,1H3,(H,24,26)(H2,21,22,23,25)

Standard InChI Key:  UOTDFXYEFWAKEU-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   -5.3352   -0.2148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5102   -0.2148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0394   -0.8685    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2351   -0.6183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2351    0.2069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0180    0.4528    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5249    0.6187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8085    0.2106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8085   -0.6179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5231   -1.0302    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0940   -1.0304    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3793   -0.6179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3379   -1.0322    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0496   -0.6158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0496    0.2051    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3333    0.6177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3793    0.2071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0938    0.6196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7641   -1.0282    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4786   -0.6158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4786    0.2092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1915    0.6198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9062    0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9062   -0.6137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1961   -1.0301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6207    0.6197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3352    1.0322    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  1  0
  5  4  2  0
  5  6  1  0
  6  2  1  0
  7  5  1  0
  8  7  2  0
  9  8  1  0
 10  9  2  0
  4 10  1  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 12  2  0
 17 18  1  0
 14 19  1  0
 19 20  1  0
 21 20  2  0
 22 21  1  0
 23 22  2  0
 24 23  1  0
 25 24  2  0
 20 25  1  0
 26 23  1  0
 26 27  3  0
M  END

Associated Targets(Human)

JAK3 Tclin JAK3/JAK1 (270 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 358.36Molecular Weight (Monoisotopic): 358.1178AlogP: 3.58#Rotatable Bonds: 4
Polar Surface Area: 119.63Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 9.44CX Basic pKa: 4.39CX LogP: 3.93CX LogD: 3.93
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.51Np Likeness Score: -1.38

References

1. Chen Y, Li H, Yen R, Heckrodt TJ, McMurtrie D, Singh R, Taylor V, Masuda ES, Park G, Payan DG..  (2022)  Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.,  13  (11.0): [PMID:36385926] [10.1021/acsmedchemlett.2c00411]

Source